Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
For the treatment of pneumonia due to Pneumocystis carinii.
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States
Holmes Hosp, Cincinnati, Ohio, United States
Hampton Roads Med Specialists, Hampton, Virginia, United States
Bay Area AIDS Consortium, Tampa, Florida, United States
SUNY - Stony Brook, Stony Brook, New York, United States
Justus-Leibig University, Giessen, Germany
University of Alberta, Edmonton, Alberta, Canada
University of Geneva, Geneva, Switzerland
LyphoMed Inc, Rosemont, Illinois, United States
Chicago Children's CRS, Chicago, Illinois, United States
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
Case CRS, Cleveland, Ohio, United States
SUNY - Stony Brook, Stony Brook, New York, United States
Usc La Nichd Crs, Los Angeles, California, United States
Chicago Children's CRS, Chicago, Illinois, United States
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.